Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner

Jun Saegusa, Nobuaki Akakura, Chun Yi Wu, Case Hoogland, Zi Ma, Kit S. Lam, Fu Tong Liu, Yoko K. Takada, Yoshikazu Takada

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis of inflammatory diseases. Catalytic activity of this enzyme that generates arachidonic acid is a major target for development of anti-inflammatory agents. Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor-mediated mechanism (e.g. through the M-type receptor). However, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and rabbits, but not in human. Thus sPLA2-IIA receptors in human have not been established. Here we demonstrated that sPLA2-IIA bound to integrin αvβ3 at a high affinity (KD = 2 × 10-7 M). We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for integrin binding using docking simulation and mutagenesis. The integrin-binding site did not include the catalytic center or the M-type receptor-binding site. sPLA2-IIA also bound to α4β1. We showed that sPLA2-IIA competed with VCAM-1 for binding to α4β1, and bound to a site close to those for VCAM-1 and CS-1 in the α4 subunit. Wild type and the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activation in monocytic cells, but the integrin binding-defective R74E/R100E mutant did not. This indicates that integrin binding is required, but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling. These results suggest that integrins αvβ3 and α4β1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

Original languageEnglish
Pages (from-to)26107-26115
Number of pages9
JournalJournal of Biological Chemistry
Volume283
Issue number38
DOIs
Publication statusPublished - Sep 19 2008
Externally publishedYes

Fingerprint

Group II Phospholipases A2
Secretory Phospholipase A2
Integrins
Cell Proliferation
Catalyst activity
Vascular Cell Adhesion Molecule-1
Binding Sites
Mutagenesis
Cell proliferation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner. / Saegusa, Jun; Akakura, Nobuaki; Wu, Chun Yi; Hoogland, Case; Ma, Zi; Lam, Kit S.; Liu, Fu Tong; Takada, Yoko K.; Takada, Yoshikazu.

In: Journal of Biological Chemistry, Vol. 283, No. 38, 19.09.2008, p. 26107-26115.

Research output: Contribution to journalArticle

Saegusa, Jun ; Akakura, Nobuaki ; Wu, Chun Yi ; Hoogland, Case ; Ma, Zi ; Lam, Kit S. ; Liu, Fu Tong ; Takada, Yoko K. ; Takada, Yoshikazu. / Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 38. pp. 26107-26115.
@article{98b1f73d5e4541f9afabe6928a106eb7,
title = "Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner",
abstract = "Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis of inflammatory diseases. Catalytic activity of this enzyme that generates arachidonic acid is a major target for development of anti-inflammatory agents. Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor-mediated mechanism (e.g. through the M-type receptor). However, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and rabbits, but not in human. Thus sPLA2-IIA receptors in human have not been established. Here we demonstrated that sPLA2-IIA bound to integrin αvβ3 at a high affinity (KD = 2 × 10-7 M). We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for integrin binding using docking simulation and mutagenesis. The integrin-binding site did not include the catalytic center or the M-type receptor-binding site. sPLA2-IIA also bound to α4β1. We showed that sPLA2-IIA competed with VCAM-1 for binding to α4β1, and bound to a site close to those for VCAM-1 and CS-1 in the α4 subunit. Wild type and the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activation in monocytic cells, but the integrin binding-defective R74E/R100E mutant did not. This indicates that integrin binding is required, but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling. These results suggest that integrins αvβ3 and α4β1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.",
author = "Jun Saegusa and Nobuaki Akakura and Wu, {Chun Yi} and Case Hoogland and Zi Ma and Lam, {Kit S.} and Liu, {Fu Tong} and Takada, {Yoko K.} and Yoshikazu Takada",
year = "2008",
month = "9",
day = "19",
doi = "10.1074/jbc.M804835200",
language = "English",
volume = "283",
pages = "26107--26115",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "38",

}

TY - JOUR

T1 - Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner

AU - Saegusa, Jun

AU - Akakura, Nobuaki

AU - Wu, Chun Yi

AU - Hoogland, Case

AU - Ma, Zi

AU - Lam, Kit S.

AU - Liu, Fu Tong

AU - Takada, Yoko K.

AU - Takada, Yoshikazu

PY - 2008/9/19

Y1 - 2008/9/19

N2 - Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis of inflammatory diseases. Catalytic activity of this enzyme that generates arachidonic acid is a major target for development of anti-inflammatory agents. Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor-mediated mechanism (e.g. through the M-type receptor). However, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and rabbits, but not in human. Thus sPLA2-IIA receptors in human have not been established. Here we demonstrated that sPLA2-IIA bound to integrin αvβ3 at a high affinity (KD = 2 × 10-7 M). We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for integrin binding using docking simulation and mutagenesis. The integrin-binding site did not include the catalytic center or the M-type receptor-binding site. sPLA2-IIA also bound to α4β1. We showed that sPLA2-IIA competed with VCAM-1 for binding to α4β1, and bound to a site close to those for VCAM-1 and CS-1 in the α4 subunit. Wild type and the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activation in monocytic cells, but the integrin binding-defective R74E/R100E mutant did not. This indicates that integrin binding is required, but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling. These results suggest that integrins αvβ3 and α4β1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

AB - Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis of inflammatory diseases. Catalytic activity of this enzyme that generates arachidonic acid is a major target for development of anti-inflammatory agents. Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor-mediated mechanism (e.g. through the M-type receptor). However, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and rabbits, but not in human. Thus sPLA2-IIA receptors in human have not been established. Here we demonstrated that sPLA2-IIA bound to integrin αvβ3 at a high affinity (KD = 2 × 10-7 M). We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for integrin binding using docking simulation and mutagenesis. The integrin-binding site did not include the catalytic center or the M-type receptor-binding site. sPLA2-IIA also bound to α4β1. We showed that sPLA2-IIA competed with VCAM-1 for binding to α4β1, and bound to a site close to those for VCAM-1 and CS-1 in the α4 subunit. Wild type and the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activation in monocytic cells, but the integrin binding-defective R74E/R100E mutant did not. This indicates that integrin binding is required, but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling. These results suggest that integrins αvβ3 and α4β1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=54449088685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449088685&partnerID=8YFLogxK

U2 - 10.1074/jbc.M804835200

DO - 10.1074/jbc.M804835200

M3 - Article

C2 - 18635536

AN - SCOPUS:54449088685

VL - 283

SP - 26107

EP - 26115

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 38

ER -